Division of Basic Medical Research FY2019 List of Projects - Research Program on Hepatitis
Program for Basic and Clinical Research on Hepatitis
| First Year | Principal Investigator | Affiliation | Project Title | |
|---|---|---|---|---|
| FY2017 | Shuji Terai | Niigata University | Professor | Mechanistic analysis of combination therapy with mesenchymal stem cells and macrophages against liver cirrhosis using state-of-the-art live imaging techniques and exosomes |
| FY2017 | Naoya Sakamoto | Hokkaido University | Professor | Studies for the mechanisms of histopathological progression in chronic liver diseases and comprehensive glycomic analyses for the biomarkers of prognostic prediction |
| FY2017 | Hiroshi Yatsuhashi | National Hospital Organization Nagasaki Medical Center | Vice President | Research for grasping the actual condition of patients with liver cirrhosis including the prognosis |
| FY2017 | Kazuaki Chayama | Hiroshima University | Professor | A comprehensive study evaluating life expectancy, pathogenesis and quality of life after hepatitis C virus |
| FY2017 | Tetsuo Takehara | Osaka University | Professor | Study of HCV eradicated-liver using HCV-infection model and clinical cohort |
| FY2017 | Hideki Aizaki | National Institute of Infectious Diseases | Chief | Study on pathological conditions after sustained virological response of hepatitis C virus |
| FY2017 | Yoshihiko Maehara | Fukuoka Dental College | Visiting Professor | Multi-center study for establishment of standard treatment for recurrent viral hepatitis after liver transplantation |
| FY2017 | Hitoshi Tajiri | Osaka General Medical Center | Executive Adviser | Studies on clinical issues of viral hepatitis during childhood and on updating a practice guideline |
| FY2017 | Namiki Izumi | Musashino Red Cross Hospital | President | Establishment of Treatment Strategy with direct acting antivirals (DAAs) based on Nationwide Resistance Associated Substitution Analysis of hepatitis C virus after failure of first generation DAAs |
| FY2017 | Takahiro Kodama | Osaka University | Assistant Professor | Discovery and characterization of NASH-derived HCC drivers through forward genetic screens and omics |
| FY2017 | Itoh Yoshito | Kyoto Prefectural University of Medicine |
Professor | Apg-2 plays an essential role for the progression of nonalcoholic liver diseases; its application for a useful biomarker and for the development of a novel pharmaceutical agents |
| FY2017 | Koh Ono | Kyoto University | Associate Professor | Development of novel strategy for the treatment of NAFLD/NASH by the inhibition of miR-33a/b, which are important for cholesterol metabolism |
| FY2017 | Michio Nakaya | Kyushu University | Associate Professor | Functional analysis of a fibrosis-stimulating receptor, which is specifically expressed in myofibroblasts, and the development of a novel strategy for targeting the receptor to treat liver fibrosis |
| FY2017 | Yukio Nagasaki | University of Tsukuba | Professor | Development of High Performance Nanomedicines for Chronic Inflammatory Liver Diseases |
| FY2017 | Toshiji Saibara | Kochi Medical School | Professor | Development of pre-emptive medicine for NAFLD using lipidglycome |
| FY2017 | Taro Yamashita | Kanazawa University | Associate Professor | Development of a new therapy to normalize the remodeling of liver associated with hepatic fibrosis |
| FY2018 | Yoichi Hiasa | Ehime University | Professor | Establishment of clinical immunotherapy against hepatitis B virus to stop the administration of nucleotide analogue |
| FY2018 | Kazumoto Murata | International University of Health and Welfare | Professor | Investigation for new therapeutic strategies and drug-discovery for withdrawal of drugs in HBV infection, based on novel cytokines’ production by nucleotide analogues |
| FY2018 | Masashi Mizokami | National Center for Global Health and Medicine | Project Leader | Development of cost-effective prevention protocols and elucidation of the mechanism for hepatitis B reactivation |
| FY2018 | Koichi Watashi | National Institute of Infectious Diseases | Senior Researcher | Nuclear hormone receptor ligands for controlling difficult-to-treat hepatitis C and steatohepatitis |
| FY2018 | Takanori Takebe | Tokyo Medical and Dental University | Professor | Development of human NAFLD organoid panel for innovative drug screening |
| FY2018 | Akihiro Umezawa | National Center for Child Health and Development | Director | Development of novel embryonic stem cell-based products for liver cirrhosis and liver failure |
| FY2018 | Yutaka Inagaki | Tokai University | Professor | Novel Diagnostic and Treatment Strategies for Regeneration of Fibrotic Liver by Focusing on an Exosome-carrying Regenerating Factor |
| FY2018 | Kazuhiko Koike | The University of Tokyo | Professor | Study on the pathogenesis of metabolism-associated liver cancer including those associated with viral hepatitis |
| FY2018 | Tatsuya Kanto | National Center for Global Health and Medicine | Director General | Development of tailored medicine for NASH patients with liver cancer based on lipidgenomics research |
| FY2018 | Hiroshi Nishina | Tokyo Medical and Dental University | Professor | Study of an innovative HBV-related liver disease therapy based on abnormal hepatocyte elimination |
| FY2018 | Hiroaki Okamoto | Jichi Medical University | Professor | Study on Infection Prevention, Pathogenesis and Treatment of Orallytransmitted Viral Hepatitis A and E |
| FY2018 | Riki Toita | National Institute of Advanced Industrial Science and Technology |
Researcher | Development of inflammatory immune cell-targeted nanomedicine for the prevention and treatment of NASH/NAFLD |
| FY2018 | Sachiyo Yoshio | National Center for Global Health and Medicine | Chief | Development of novel therapy for the patients with cirrhosis based on immunological analysis targeting muscle-liver axis |
| FY2018 | Takayoshi Shirasaki | Kanazawa University | Assistant Professor | Studies on a novel immune control mechanism against liver diseases |
| FY2019 | Nobuyuki Enomoto | University of Yamanashi | Professor | Study on factors influencing post treatment pathological status in hepatitis C patients receiving direct acting antiviral agents using next generation sequencing technology |
| FY2019 | Yasuhito Tanaka | Nagoya City University | Professor | Genome-wide research aimed at identifying host factors affecting the changes in disease conditions after direct acting antiviral therapies for hepatitis C |
| FY2019 | Shuichi Kaneko | Kanazawa University | Professor | Study of preventing hepatocarcinogenesis from chronic hepatitis C |
| FY2019 | Norifumi Kawada | Osaka City University | Professor | Study on the development of regression therapy for liver fibrosis by using recombinant human Cytoglobin |
| FY2019 | Hideki Ohdan | Hiroshima University | Professor | Research and development of immune-therapy using pluripotent stem cells as potential anti-hepatitis/hepatoma therapeutics |
| FY2019 | Naoya Kato | Chiba University | Professor | Development of Hepatocarcinogenesis Prevention in Hepatitis C by Activating Innate Immune Response |
| FY2019 | Masamichi Muramatsu | National Institute of Infectious Diseases | Director | Basic research and development of novel diagnostic and therapeutic approaches for viral hepatitis |
| FY2019 | Motoyuki Otsuka | The University of Tokyo | Assistant Professor | Development of novel interventional methods against hepatitis B based on the comprehensive elucidation of its pathogenesis |
| FY2019 | Toru Okamoto | Osaka University | Associate Professor | Development of novel therapeutics for pathogenesis induced by hepatitis viruses |
| FY2019 | Katsushi Tokunaga | National Center for Global Health and Medicine | Co-Director, Genome Medical Science Project | Study for clinical sequencing based on genome analysis of host and viral factors |
| FY2019 | Takuya Yamamoto | National Institutes of Biomedical Innovation, Health and Nutrition | Project Leader | Establishment of therapeutic strategies toward a functional cure for HBV by innovative immunotherapies |
| FY2019 | Tetsuo Takehara | Osaka University | Professor | Study of outcome of liver cirrhotic patients received HCV elimination therapy |
| FY2019 | Hayato Nakagawa | The University of Tokyo | Assistant Professor | Relevance of burned-out phenomenon to the pathogenesis of NASH: Development of a new therapeutic strategy based on lipid metabolism |
| FY2019 | Yasuhiro Asahina | Tokyo Medical and Dental University | Professor | Development of an innovative disease model using human iPS cell-derived liver organoids and creation of treatments to suppress hepatic fibrosis and hepatocarcinogenesis |
| FY2019 | Masaya Sugiyama | National Center for Global Health and Medicine | Vice Director | Development of full-length HBV-POL expression system for drug discovery |
| FY2019 | Daisuke Yamane | Tokyo Metropolitan Institute of Medical Science | Chief Researcher | Study of Intrinsic Antiviral Signaling Pathways in Hepatocytes Toward the Development of Novel Antiviral Strategies |
| FY2019 | Kazuo Takayama | Osaka University | Assistant Professor | Functional analysis and regulation of liver disease-associated gene TLL1 |
Program on the Innovative Development and the Application of New Drugs for Hepatitis B
| First Year | Principal Investigator | Affiliation | Project Title | |
|---|---|---|---|---|
| FY2017 | Yasuhito Tanaka | Nagoya City University | Professor | Drug screening for developing HBV therapeutics and optimization of the hit compounds |
| FY2017 | Kyoji Moriya | The University of Tokyo | Professor | Search for drug candidates with novel mechanisms capable of efficient inhibition of hepatitis B virus propagation |
| FY2017 | Masamichi Muramatsu | National Institute for Infectious Diseases | Director | Basic research on hepatitis B virus life cycle and anti-viral development |
| FY2017 | Kunitada Shimotohno | National Center for Global Medicine and Health | Project Chief | Analysis of HBV life cycle by using sophisticated reporter HBV systems and its application to the development of a new strategy to suppress HBV infection and replication |
| FY2017 | Keiji Ueda | Osaka University | Professor | Exploitation of anti-HBV strategies by targeting cellular factors functioning in the HBV life cycle |
| FY2017 | Tatsuya Kanto | National Center for Global Health and Medicine | Director General | Establishment of novel therapeutic strategies against HBV - An integrated Immuno-omics approach |
| FY2017 | Takashi Fujita | Kyoto University | Professor | Research for HBV therapy development based on the establishment of HBV-sensitive cell and animal models |
| FY2017 | Tetsuo Takehara | Osaka University | Professor | Development of molecular pathogenesis and drug discovery using HBV infection models |
| FY2017 | Kazuaki Chayama | Hiroshima University | Professor | Hepatitis B virus eradication therapy development using a highly efficient cell culture system and a long term active chronic hepatitis B mouse model |
| FY2017 | Shuichi Kaneko | Kanazawa University | Professor | Development of new antiviral therapies for hepatitis B virus |
| FY2017 | Masashi Mizokami | National Center for Global Health and Medicine | Project Leader | Comprehensive development of innovative therapeutic methods for complete inactivation of the HBV genome in the liver through application of genome-editing technology in personalized medicine |
| FY2017 | Soichi Kojima | RIKEN | Unit leader | Drug discovery researches for licensing-out the next generation anti-HBV drugs |
| FY2017 | Hiroaki Mitsuya | Kumamoto University | Distinguished Guest Professor | Development of novel anti-hepatitis B virus (HBV) agents potent against wild-type- and drug-resistant-HBVs |
| FY2017 | Koichi Watashi | National Institute of Infectious Diseases | Senior Researcher | Drug development against hepatitis B virus using chemical biological approaches and mathematical models |
| FY2017 | Nao Nishida | National Center for Global Health and Medicine | Senior Fellow | Further clarification of mechanisms of chronic hepatitis B infection, viral clearance, and development of hepatocellular carcinoma |
| FY2017 | Yasunari Nakamoto | University of Fukui | Professor | Development of Antiviral Therapy for Elimination of Intranuclear Hepatitis B Virus Covalently Closed Circular DNA by Activation of Acquired Immune Responses |
| FY2017 | Ryo Sumazaki | University of Tsukuba | Professor | Identification of a biomarker for hepatitis B surface antigen (HBsAg) clearance and development of a new hepatitis B vaccine |
| FY2017 | Kiyoaki Ito | Aichi Medical University | Professor | Regulation of hepatitis B virus targeting by the control mechanisms of bile acid metabolism |
| FY2017 | Yoshiharu Matsuura | Osaka University | Director, Professor | Identification and evaluation of host factors involved in HBV life cycle |
| FY2017 | Takanobu Kato | National Institute of Infectious Diseases | Laboratory chief | Establishment of novel effective hepatitis B vaccine containing preS1 region |
Last updated 08/06/19